Update on gout and hyperuricemia

International Journal of Clinical Practice

Volumn 64, Issue 3, 2010, Pages 371-377

  Baker, J F ^a   Ralph Schumacher, H ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; COLCHICINE; FEBUXOSTAT; INDOMETACIN; NAPROXEN; PREDNISOLONE; PREDNISONE; PROBENECID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ABSENCE OF SIDE EFFECTS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; KIDNEY DISEASE; LOW DRUG DOSE; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW;

ACUTE DISEASE; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COST OF ILLNESS; EARLY DIAGNOSIS; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; KIDNEY DISEASES; QUALITY OF LIFE; RISK FACTORS;

EID: 74349093688     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02188.x     Document Type: Review

References (60)

1. Mikuls TR, Farrar JT, Bilker WB et al. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005 64 : 267 272.
2. Lawrence RC, Felson DT, Helmick CG et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008 58 : 26 35.
3. Nan H, Qiao Q, Dong Y et al. The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J Rheumatol 2006 33 : 1346 1350.
4. Choi HK, Ford E. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med 2007 120 : 442 447.
5. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008 93 (11 Suppl. 1 S9 30.
6. Bantle JP. Dietary fructose and metabolic syndrome and diabetes. J Nutr 2009 139 : 1263S 8S.
7. Choi JWJ, Ford ES, Gao X, Choi HK. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008 59 : 109 116.
8. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford) 2007 46 : 1441 1444.
9. Halpern R, Fuldeore MJ, Mody RR, Patel PA. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009 15 : 3 7.
10. Kim KY, Schumacher HR. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003 25 : 1593 1617.
11. Wu EQ, Patel PA. Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm 2008 14 : 164 175.
12. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisationin US veterans. Ann Rheum Dis 2008 67 : 1310 1316.
13. Kleinman NL, Brook RA. The impact of gout on work absence and productivity. Value Health 2007 10 : 231 237.
14. Zhang W, Doherty M, Pascual E et al. EULAR evidence based recommendations for gout - part 1 diagnosis: report of a task force on the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006 65 : 1301 1311. (Pubitemid 44641591)
15. Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol 2009 15 : 22 4.
16. Agudelo CA, Weinberger A, Schumacher HR et al. Definitive diagnosis of gout by identification of urate crystals in asymptomatic metatarsophalangeal joints. Arthritis Rheum 1979 22 : 559 560.
17. Schlesinger N, Norquist JM, Watson DJ. Serum Urate During Acute Gout. J Rheumatol 2009 36 : 1287 1289.
18. Alappatt C, Clayburne G, Schumacher R. Concomitant polyarticular septic and gouty arthritis. J Rheumatol 2006 33 : 1707 1708.
19. Hamilton ME, Parris TM, Gibson RS, Davis JS. Simultaneous gout and pyarthrosis. Arch Intern Med 1980 140 : 917 919.
20. Zhang W, Doherty M, Bardin T et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006 65 : 1312 1324. (Pubitemid 44620440)
21. Janssens HJ, Janssen M, van de Lisdonk EH et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008 371 : 1854 1860.
22. Fernandez C, Noguera R, Gonzalez JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999 26 : 2285 2286.
23. Dalbeth N, Stamp L. Allopurinol dosing and renal impairment: walking the tightrope between adequate urate lowering and adverse events. Semin Dial 2007 20 : 391 395.
24. Pluim HJ, Deuren Mv, Wetzels JF. The allopurinol hypersensitivity syndrome. Neth J Med 1998 52 : 107 110.
25. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984 76 : 47 56.
26. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009 11 : 135 140.
27. Hung SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci 2005 102 : 6237.
28. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001 60 : 981 983.
29. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008 31 : 643 665.
30. Taniguchi A, Kamatani N. Control of renal uric acid excretion and gout. Curr Opin Rheumatol 2008 20 : 192 197.
31. McGonagle D, Tan AL, Shankaranarayana S et al. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann Rheum Dis 2007 66 : 1683 1684.
32. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007 9 : R28.
33. Sundy J, Terkeltaub R, Schumacher HR. Placebo-controlled pilot study of rilonacept (IL-Trap), a long acting IL-1 inhibitor, in refractory chronic gouty arthritis [abstract]. Ann Rheum Dis 2008 67 (Suppl. II 97.
34. Schumacher HR, Becker MA, Wortmann RL et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008 59 : 1540 1548.
35. Sundy JS, Becker MA, Baraf HS et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 2008 58 : 2882 2891.
36. Ganson NJ, Kelly SJ, Scarlett E et al. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 2006 8 : R12.
37. Sherman MR, Saifer MGP, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008 60 : 59 68.
38. Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum 2007 57 : 816 821.
39. Hamada T, Ichida K, Hosoyamada M et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008 21 : 1157 1162.
40. Huang HY, Appel LJ, Choi MJ et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum 2005 52 : 1843 1847.
41. Lee YH, Lee C-H, Lee J. Effect of fenofibrate in combination with urate lowering agents in patients with gout. Korean J Intern Med 2006 21 : 89 93.
42. Roseff R, Wohlgethan JR, Sipe JD, Canoso JJ. The acute phase response in gout. J Rheumatol 1987 14 : 974 977.
43. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000 342 : 836 843. (Pubitemid 30165206)
44. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006 54 : 2688 2696.
45. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007 116 : 894 900.
46. Krishnan E, Svendsen K, Neaton JD et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008 168 : 1104 1110.
47. Vasquez-Mellado J, Garcia CG, Vasquez SG et al. Metabolic syndrome and ischemic heart disease in gout. J Clin Rheumatol 2004 10 : 105 109.
48. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005 118 : 816 826.
49. Tavil Y, Kaya MG, Oktar SO et al. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis 2008 197 : 159 163.
50. Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial Angiology 2007 58 : 450 457.
51. Chen J, Chuang S, Chen H et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009 61 : 225 232.
52. Tang Z, Cheng L-T, Li H-Y, Wang T. Serum uric acid and endothelial dysfunction in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 2009 29 : 368 373.
53. Khosla UM, Zharikov S, Finch JL et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005 67 : 1739 1742.
54. Feig DI, Kang DH, Nakagawa T et al. Uric acid and hypertension. Curr Hypertens Rep 2006 8 : 111 115.
55. Kanellis J, Kang D-H. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol 2005 25 : 39 42.
56. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008 300 : 924 932.
57. Siu YP, Leung K-T, Tong MK-H, Kwan T-H. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006 47 : 51 9.
58. Avram Z, Krishnan E. Hyperuricaemia - where nephrology meets rheumatology. Rheumatology (Oxford) 2008 47 : 960 964.
59. Madero M, Sarnak MJ, Wang X et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009 53 : 796 803.
60. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007 27 : 435 440.